Progressive pulmonary fibrosis: an expert group consensus statement

This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on mon...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The European respiratory journal Ročník 61; číslo 3
Hlavní autoři:	Rajan, Sujeet K, Cottin, Vincent, Dhar, Raja, Danoff, Sonye, Flaherty, Kevin R, Brown, Kevin K, Mohan, Anant, Renzoni, Elizabeth, Mohan, Murali, Udwadia, Zarir, Shenoy, Padmanabha, Currow, David, Devraj, Anand, Jankharia, Bhavin, Kulshrestha, Ritu, Jones, Steve, Ravaglia, Claudia, Quadrelli, Silvia, Iyer, Rajam, Dhooria, Sahajal, Kolb, Martin, Wells, Athol U
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.03.2023
Témata:	Artificial Intelligence Disease Progression Fibrosis Humans Idiopathic Pulmonary Fibrosis - diagnosis Idiopathic Pulmonary Fibrosis - therapy Lung Diseases, Interstitial - diagnosis Lung Diseases, Interstitial - therapy Pulmonary Fibrosis - diagnosis Pulmonary Fibrosis - therapy
ISSN:	1399-3003, 1399-3003
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term "progressive pulmonary fibrosis" (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management.
AbstractList	This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term "progressive pulmonary fibrosis" (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management. This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term "progressive pulmonary fibrosis" (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management.This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term "progressive pulmonary fibrosis" (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management.
Author	Renzoni, Elizabeth Dhooria, Sahajal Mohan, Anant Mohan, Murali Flaherty, Kevin R Shenoy, Padmanabha Quadrelli, Silvia Cottin, Vincent Danoff, Sonye Jones, Steve Kolb, Martin Iyer, Rajam Dhar, Raja Udwadia, Zarir Brown, Kevin K Devraj, Anand Kulshrestha, Ritu Wells, Athol U Jankharia, Bhavin Rajan, Sujeet K Ravaglia, Claudia Currow, David
Author_xml	– sequence: 1 givenname: Sujeet K orcidid: 0000-0001-7955-2147 surname: Rajan fullname: Rajan, Sujeet K email: skrajan@hotmail.com organization: Bombay Hospital Institute of Medical Sciences and Bhatia Hospital, Mumbai, India skrajan@hotmail.com – sequence: 2 givenname: Vincent orcidid: 0000-0002-5591-0955 surname: Cottin fullname: Cottin, Vincent organization: National French Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INRAE, Member of ERN-LUNG, Lyon, France – sequence: 3 givenname: Raja surname: Dhar fullname: Dhar, Raja organization: CK Birla Hospitals, Kolkata, India – sequence: 4 givenname: Sonye surname: Danoff fullname: Danoff, Sonye organization: Johns Hopkins School of Medicine, Baltimore, MD, USA – sequence: 5 givenname: Kevin R surname: Flaherty fullname: Flaherty, Kevin R organization: University of Michigan, Ann Arbor, MI, USA – sequence: 6 givenname: Kevin K surname: Brown fullname: Brown, Kevin K organization: Department of Medicine, National Jewish Health, Denver, CO, USA – sequence: 7 givenname: Anant surname: Mohan fullname: Mohan, Anant organization: All India Institute of Medical Sciences, New Delhi, India – sequence: 8 givenname: Elizabeth surname: Renzoni fullname: Renzoni, Elizabeth organization: Royal Brompton Hospital/Imperial College London, London, UK – sequence: 9 givenname: Murali surname: Mohan fullname: Mohan, Murali organization: Narayana Health, Bengaluru, India – sequence: 10 givenname: Zarir surname: Udwadia fullname: Udwadia, Zarir organization: Breach Candy Hospital, Mumbai, India – sequence: 11 givenname: Padmanabha surname: Shenoy fullname: Shenoy, Padmanabha organization: Department of Rheumatology, Centre for Arthritis and Rheumatism Excellence, Kochi, India – sequence: 12 givenname: David surname: Currow fullname: Currow, David organization: University of Technology, Sydney, Australia – sequence: 13 givenname: Anand surname: Devraj fullname: Devraj, Anand organization: Department of Radiology, Royal Brompton Hospital, London, UK – sequence: 14 givenname: Bhavin surname: Jankharia fullname: Jankharia, Bhavin organization: Picture This by Jankharia, Mumbai, India – sequence: 15 givenname: Ritu surname: Kulshrestha fullname: Kulshrestha, Ritu organization: Department of Pathology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India – sequence: 16 givenname: Steve surname: Jones fullname: Jones, Steve organization: European Idiopathic Pulmonary Fibrosis Federation (EU-IPFF), Peterborough, UK – sequence: 17 givenname: Claudia surname: Ravaglia fullname: Ravaglia, Claudia organization: Pulmonology Unit, GB Morgagni Hospital/University of Bologna, Forlì, Italy – sequence: 18 givenname: Silvia surname: Quadrelli fullname: Quadrelli, Silvia organization: Hospital Britanico de Buenos Aires, Buenos Aires, Argentina – sequence: 19 givenname: Rajam surname: Iyer fullname: Iyer, Rajam organization: Bhatia Hospital and PD Hinduja Hospital, Mumbai, India – sequence: 20 givenname: Sahajal orcidid: 0000-0003-3199-9163 surname: Dhooria fullname: Dhooria, Sahajal organization: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India – sequence: 21 givenname: Martin orcidid: 0000-0003-3837-1467 surname: Kolb fullname: Kolb, Martin organization: Co-senior authors – sequence: 22 givenname: Athol U surname: Wells fullname: Wells, Athol U organization: Co-senior authors
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36517177$$D View this record in MEDLINE/PubMed
BookMark	eNpNj0tLxDAUhYOMOA_9BYJk6aaaR9O07mTwBQO60HVJ0puh0iY1txX9987gCK7Ox8fhwFmSWYgBCDnn7IrzUl5zWVWSMXnFJC91JpjgR2Sxt9lez_7xnCwR3xnjRS75CZnLQnHNtV6Q9UuK2wSI7SfQYer6GEz6pr61KWKLN9QECl8DpJFuU5wG6mJACDghxdGM0EMYT8mxNx3C2SFX5O3-7nX9mG2eH57Wt5vM5VqMmZbOFqVSykuAyuYOKl3qhlcWSunFjryVeQ6eN8oL50AzI41gXHJjFTRiRS5_d4cUPybAse5bdNB1JkCcsBZa5WXBhNa76sWhOtkemnpIbb_7Vf8dFz9zf13e
CitedBy_id	crossref_primary_10_1002_acr_25348 crossref_primary_10_5826_mrm_2025_1026 crossref_primary_10_1016_j_rmed_2025_108347 crossref_primary_10_1016_j_reumae_2023_12_010 crossref_primary_10_1093_rheumatology_keaf306 crossref_primary_10_1016_j_prmcm_2024_100404 crossref_primary_10_1177_17534666251335774 crossref_primary_10_1186_s12967_025_07020_1 crossref_primary_10_1183_13993003_01852_2023 crossref_primary_10_1097_MD_0000000000038642 crossref_primary_10_1002_mco2_744 crossref_primary_10_1016_j_taap_2025_117524 crossref_primary_10_1016_j_cyto_2025_156906 crossref_primary_10_46847_ujmm_2025_2_6__024 crossref_primary_10_1111_imj_70051 crossref_primary_10_1007_s41030_025_00302_5 crossref_primary_10_1007_s00296_025_05934_z crossref_primary_10_1016_j_autrev_2025_103900 crossref_primary_10_3390_jpm14070708 crossref_primary_10_3390_diagnostics15030278 crossref_primary_10_1093_bjro_tzaf018 crossref_primary_10_1016_j_autrev_2024_103582 crossref_primary_10_1186_s12964_024_01966_3 crossref_primary_10_1080_03009742_2024_2327159 crossref_primary_10_3390_diagnostics15172179 crossref_primary_10_1183_23120541_00403_2024 crossref_primary_10_1002_rcr2_1446 crossref_primary_10_1080_17843286_2023_2280737 crossref_primary_10_1007_s11845_024_03848_6 crossref_primary_10_1038_s41598_025_93221_z crossref_primary_10_1186_s13019_025_03511_w crossref_primary_10_3390_jor5030014 crossref_primary_10_1007_s40801_025_00515_9 crossref_primary_10_1016_j_chpulm_2024_100124 crossref_primary_10_1186_s12890_025_03554_8 crossref_primary_10_18093_0869_0189_2025_35_4_476_481 crossref_primary_10_1183_16000617_0023_2025 crossref_primary_10_1055_s_0044_1786698 crossref_primary_10_3389_fimmu_2024_1479458 crossref_primary_10_1016_j_ccm_2023_08_011 crossref_primary_10_1093_rheumatology_keae271 crossref_primary_10_3390_jcm14134631 crossref_primary_10_17116_respmed2025102151 crossref_primary_10_3390_biom14030247 crossref_primary_10_1183_20734735_0172_2024 crossref_primary_10_1186_s12890_024_03151_1 crossref_primary_10_1016_j_rmed_2025_108353 crossref_primary_10_1186_s12931_024_02987_9 crossref_primary_10_1136_bmjresp_2024_002368 crossref_primary_10_1164_rccm_202308_1523ED crossref_primary_10_1186_s12931_024_03070_z crossref_primary_10_1002_mco2_70128 crossref_primary_10_1016_j_resinv_2025_06_017 crossref_primary_10_3390_jcm14186420 crossref_primary_10_3390_medicina61091646 crossref_primary_10_1016_j_hrtlng_2024_07_010 crossref_primary_10_1080_17476348_2024_2375420 crossref_primary_10_3389_fmed_2024_1393778 crossref_primary_10_1080_17476348_2024_2331763 crossref_primary_10_3390_jcm14186665 crossref_primary_10_7759_cureus_45678 crossref_primary_10_1016_j_semarthrit_2025_152710 crossref_primary_10_21518_ms2025_064 crossref_primary_10_2169_naika_113_1712 crossref_primary_10_7759_cureus_88645 crossref_primary_10_1080_07853890_2024_2406439 crossref_primary_10_3390_biomedicines11071834 crossref_primary_10_1038_s41598_025_08969_1 crossref_primary_10_1177_17534666241288417 crossref_primary_10_1016_j_resmer_2024_101140 crossref_primary_10_1111_1756_185X_15208 crossref_primary_10_1177_17534666241266343 crossref_primary_10_1007_s12325_023_02668_x crossref_primary_10_3390_jcm13216508 crossref_primary_10_1186_s12931_024_02997_7 crossref_primary_10_3390_life14091203 crossref_primary_10_1177_09636897241281026 crossref_primary_10_3389_fimmu_2024_1455944 crossref_primary_10_7759_cureus_53578 crossref_primary_10_7759_cureus_80290 crossref_primary_10_1186_s12931_024_02970_4 crossref_primary_10_1016_j_cnc_2025_05_002 crossref_primary_10_1080_25310429_2024_2425503 crossref_primary_10_1016_j_nantod_2024_102298 crossref_primary_10_1164_rccm_202312_2368ED crossref_primary_10_1186_s13048_024_01448_7 crossref_primary_10_3390_diagnostics14141544 crossref_primary_10_1016_j_rmed_2025_108250 crossref_primary_10_1183_16000617_0133_2024 crossref_primary_10_1016_j_bcp_2025_117283 crossref_primary_10_3389_fmed_2024_1335758 crossref_primary_10_1111_resp_70020 crossref_primary_10_1016_S2213_2600_24_00267_4 crossref_primary_10_1183_23120541_00553_2024 crossref_primary_10_26442_20751753_2025_3_203266 crossref_primary_10_12677_jcpm_2025_42138 crossref_primary_10_1186_s12890_024_03247_8 crossref_primary_10_1177_14799731241255138 crossref_primary_10_4103_pulmon_pulmon_3_25 crossref_primary_10_1097_MCP_0000000000001176 crossref_primary_10_1183_20734735_0259_2024 crossref_primary_10_1155_2024_4919951 crossref_primary_10_1016_j_ymthe_2025_09_016 crossref_primary_10_7759_cureus_78303 crossref_primary_10_1016_j_intimp_2024_112542 crossref_primary_10_1016_j_molmed_2023_08_010 crossref_primary_10_4103_atm_atm_213_24 crossref_primary_10_12998_wjcc_v12_i22_4913 crossref_primary_10_1159_000544800 crossref_primary_10_1093_jleuko_qiaf100 crossref_primary_10_3389_fmed_2024_1411279 crossref_primary_10_1097_MCP_0000000000001087 crossref_primary_10_1097_ACI_0000000000001055 crossref_primary_10_1093_rheumatology_keaf287 crossref_primary_10_1016_j_jhazmat_2024_136094 crossref_primary_10_3390_molecules28186492 crossref_primary_10_1016_j_autrev_2023_103463 crossref_primary_10_1016_j_heliyon_2024_e34592 crossref_primary_10_2478_rir_2024_0023 crossref_primary_10_1002_art_42861 crossref_primary_10_1007_s10238_023_01214_x crossref_primary_10_1016_j_resinv_2024_11_003 crossref_primary_10_3389_fmed_2025_1637654 crossref_primary_10_1148_radiol_242531 crossref_primary_10_1007_s40264_024_01400_0 crossref_primary_10_1093_rheumatology_keaf270 crossref_primary_10_1183_13993003_02215_2023 crossref_primary_10_1080_17476348_2025_2513512 crossref_primary_10_5500_wjt_v15_i3_101866 crossref_primary_10_1148_rg_230165 crossref_primary_10_3389_fmed_2024_1459785 crossref_primary_10_1513_AnnalsATS_202410_1048OC crossref_primary_10_3390_biomedicines12112439
ContentType	Journal Article
Copyright	Copyright ©The authors 2023.
Copyright_xml	– notice: Copyright ©The authors 2023.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1183/13993003.03187-2021
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1399-3003
ExternalDocumentID	36517177
Genre	Review Research Support, Non-U.S. Gov't Consensus Development Conference Journal Article
GrantInformation_xml	– fundername: Versus Arthritis grantid: 20719
GroupedDBID	--- .55 .GJ 18M 1OC 2WC 31~ 3O- 53G 5GY 5RE 5VS 8-1 AAFWJ AAZMJ ABCQX ABJNI ABOCM ABSQV ACEMG ACGFO ACPRK ACXQS ADBBV ADDZX ADMOG ADYFA AENEX AFFNX AFHIN AFZJQ AIZTS AJAOE ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CAG CGR COF CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P F9R GX1 H13 INIJC J5H KQ8 L7B LH4 LW6 NPM OK1 P2P PQQKQ R0Z RHI TER TR2 W8F WOQ X7M ZE2 ZGI ZXP ~02 7X8
ID	FETCH-LOGICAL-c472t-73cb68555f3ee9b4ce9787d19be83f27d1fb344ef1d5f2cce70a3a20131ab5ed2
IEDL.DBID	7X8
ISICitedReferencesCount	147
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001032997100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1399-3003
IngestDate	Fri Sep 05 06:34:37 EDT 2025 Sat Sep 27 02:51:20 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Language	English
License	Copyright ©The authors 2023.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c472t-73cb68555f3ee9b4ce9787d19be83f27d1fb344ef1d5f2cce70a3a20131ab5ed2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ORCID	0000-0001-7955-2147 0000-0003-3199-9163 0000-0003-3837-1467 0000-0002-5591-0955
OpenAccessLink	https://pmc.ncbi.nlm.nih.gov/articles/PMC10060665/pdf/ERJ-03187-2021.pdf
PMID	36517177
PQID	2754860277
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2754860277 pubmed_primary_36517177
PublicationCentury	2000
PublicationDate	2023-03-01
PublicationDateYYYYMMDD	2023-03-01
PublicationDate_xml	– month: 03 year: 2023 text: 2023-03-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	The European respiratory journal
PublicationTitleAlternate	Eur Respir J
PublicationYear	2023
SSID	ssj0016431
Score	2.6882079
SecondaryResourceType	review_article
Snippet	This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
SubjectTerms	Artificial Intelligence Disease Progression Fibrosis Humans Idiopathic Pulmonary Fibrosis - diagnosis Idiopathic Pulmonary Fibrosis - therapy Lung Diseases, Interstitial - diagnosis Lung Diseases, Interstitial - therapy Pulmonary Fibrosis - diagnosis Pulmonary Fibrosis - therapy
Title	Progressive pulmonary fibrosis: an expert group consensus statement
URI	https://www.ncbi.nlm.nih.gov/pubmed/36517177 https://www.proquest.com/docview/2754860277
Volume	61
WOSCitedRecordID	wos001032997100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSwMxFA5qRby4L3UjgtexM1maiReRYvHS0oNCbyUrFGSmdtqC_968zJSeBMHLzBBICI9v8ta8D6GHlHOtulYm0kudMCZZogwE8lXQfdbmqRM2kk2I4TAfj-WoCbhVTVnl-kyMB7UtDcTIO0TwyJckxPPsKwHWKMiuNhQa26hFgykDqBbjTRYhaNva4ZKQ309p03UooLgDYzD0CKAWASsk-93GjLqmf_jfXR6hg8bKxC81LI7RlitO0N6gyaOfot4IyrKgAnbl8Gz5Gaap-Tf2wXcuq2n1hFWBY-__BY7XPrCBouuiWlY43kCCkOIZ-ui_vvfekoZOITFMkEUiqNHdnHPuqXNSM-OCBylsJrXLqSfhy2vKmPOZ5Z4Y40SqqCLQkEdp7iw5RztFWbhLhCG4Q6zLRXgzrbRiYfHguaRCEZJS1Ub3a_FMAlwhB6EKVy6ryUZAbXRRy3gyq_tqTGiXZ8G7FFd_mH2N9oH4va4Gu0EtH35Wd4t2zWoxreZ3EQfhORwNfgCG5bx5
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Progressive+pulmonary+fibrosis%3A+an+expert+group+consensus+statement&rft.jtitle=The+European+respiratory+journal&rft.au=Rajan%2C+Sujeet+K&rft.au=Cottin%2C+Vincent&rft.au=Dhar%2C+Raja&rft.au=Danoff%2C+Sonye&rft.date=2023-03-01&rft.eissn=1399-3003&rft.volume=61&rft.issue=3&rft_id=info:doi/10.1183%2F13993003.03187-2021&rft_id=info%3Apmid%2F36517177&rft_id=info%3Apmid%2F36517177&rft.externalDocID=36517177
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1399-3003&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1399-3003&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1399-3003&client=summon